Absci is a biotechnology company based in New York, New York, specializing in the integration of artificial intelligence with drug discovery and development. Situated at 152 W 57th Street, this company leverages advanced generative AI technologies to design innovative biologic therapeutics. By employing data-driven approaches, Absci focuses on creating novel drug candidates aimed at challenging and traditionally difficult-to-drug targets, offering new possibilities within the pharmaceutical landscape.
The company’s approach centers around its Integrated Drug Creation platform, which combines multiple AI models for de novo design and lead optimization. These models enable the efficient identification and refinement of potential biologics, accelerating the early stages of drug development while enhancing the precision of therapeutic design. This methodology represents a shift toward computationally guided drug discovery, aligning with broader industry trends emphasizing the use of machine learning and big data in biotechnology.
Absci’s operations reflect a commitment to merging biological science with computational innovation, addressing complex problems in therapeutic design that conventional methods may struggle to solve. Their work supports efforts to improve treatment options across a range of medical conditions by targeting proteins and pathways that have been historically difficult to influence through standard pharmaceutical approaches. As a biotechnology company in New York City, Absci contributes to the region’s growing ecosystem of life sciences and technology innovation.
